Full-Time

Senior Distinguished Scientist – NCS Therapeutic Area Lead for Oncology

Psts

Posted on 11/23/2025

Deadline 12/1/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$173k - $299k/yr

+ Annual performance bonus

La Jolla, San Diego, CA, USA + 1 more

More locations: Ambler, PA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Education: Holds a Doctoral level degree (PhD, Doctor of Veterinary Medicine, Doctor of Medicine or equivalent) or Master of Science with 20+ years of direct experience.
  • At least 15 years of pharmaceutical/biotech industry experience in pre-clinical safety assessment supporting discovery/development and demonstrating progressively increasing responsibilities.
  • Oncology therapeutic area expert.
  • Development of molecules through maximum recommended doses (M3) and S6 guidelines.
  • Experience dealing with FDA or other regulatory interactions.
  • In depth knowledge of pharmaceutical science, drug development of multiple modalities including therapeutic area science and toxicology strategies, regulatory requirements/expectations for first in human approval and registration of pharmaceutics/biologics.
  • Strong verbal and written communication, appropriate for executive or high visible external venues.
  • Five or more years of people management experience.
  • Extensive matrix management experience.
  • Experience in effective coaching and mentoring.
  • Strong organizational skills and team leadership.
  • Travel up to 15% including both domestic and international.
Responsibilities
  • Be an active member of the NCSS Leadership Team.
  • Serve as the NCS Therapeutic Area Lead managing/coaching NCS Leads who work in the Oncology therapeutic area space. This includes reviewing and providing advice on tox plans, study proposals, outputs, for Immunology projects covering multiple modalities from the nomination of a target through candidate selection.
  • Act as the primary NCS participant in portfolio governance stage-gate or other review forums and provides coaching/reviewing/recommendations for diligence in the Oncology therapeutic area space, and includes interface with stakeholders in and outside of PSTS.
  • Drive strategic planning for PSTS preparedness to operate in the Oncology therapeutic area space, including NCS playbook content, providing management updates, fostering cross-industry activities and forums with regulators and external experts
  • Maintain scientific depth and expert working knowledge of competitive intelligence and regulatory landscape in oncology arena and to track milestones, issues, and attrition while highlighting strategic gaps in PSTS for action.
  • Serve as the PSTS Lead or Lead delegate as needed.
  • Lead or participate in special strategic projects as needed.
  • Maintain strong external visibility to ensure strong external reputation for PSTS.
Desired Qualifications
  • Design Mindset
  • Drug Discovery Development
  • EHS Compliance
  • Emergency Planning
  • Interpersonal Influence
  • Performance Measurement
  • Process Hazard Analysis (PHA)
  • Process Optimization
  • Program Management
  • Risk Management
  • Safety Audits
  • Safety Investigations
  • Safety-Oriented
  • Scientific Research
  • Stakeholder Engagement
  • Strategic Thinking
  • Technical Writing

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE